WO2013088257A1 - Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors - Google Patents
Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors Download PDFInfo
- Publication number
- WO2013088257A1 WO2013088257A1 PCT/IB2012/003022 IB2012003022W WO2013088257A1 WO 2013088257 A1 WO2013088257 A1 WO 2013088257A1 IB 2012003022 W IB2012003022 W IB 2012003022W WO 2013088257 A1 WO2013088257 A1 WO 2013088257A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrrolidin
- pyrazolo
- difluorophenyl
- pyridine
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *C(c1c(c(*)c(cc2)N(CCC3)C3c3ccccc3)[n]2nc1)=O Chemical compound *C(c1c(c(*)c(cc2)N(CCC3)C3c3ccccc3)[n]2nc1)=O 0.000 description 17
- JUTDHSGANMHVIC-UHFFFAOYSA-N C(C1)CNC1c1ccccc1 Chemical compound C(C1)CNC1c1ccccc1 JUTDHSGANMHVIC-UHFFFAOYSA-N 0.000 description 1
- JUTDHSGANMHVIC-JTQLQIEISA-N C(C1)CN[C@@H]1c1ccccc1 Chemical compound C(C1)CN[C@@H]1c1ccccc1 JUTDHSGANMHVIC-JTQLQIEISA-N 0.000 description 1
- JUTDHSGANMHVIC-SNVBAGLBSA-N C(C1)CN[C@H]1c1ccccc1 Chemical compound C(C1)CN[C@H]1c1ccccc1 JUTDHSGANMHVIC-SNVBAGLBSA-N 0.000 description 1
- ZFJPIQSMDBNHTN-HXUWFJFHSA-N C=C(C1)CN1C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O Chemical compound C=C(C1)CN1C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O ZFJPIQSMDBNHTN-HXUWFJFHSA-N 0.000 description 1
- TZOXCMOQUQYAPE-PIFIWZBESA-N CC(C)(C)OC(N(CC1)C(CO)CN1C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O)=O Chemical compound CC(C)(C)OC(N(CC1)C(CO)CN1C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O)=O TZOXCMOQUQYAPE-PIFIWZBESA-N 0.000 description 1
- BWLVKCALZMJBLG-XMMPIXPASA-N CC(C)(C)OC(NC(CC1)(CCN1C(c1c(cc(cc2)N(CCC3)[C@H]3c3cc(F)ccc3F)[n]2nc1)=O)C(OC)=O)=O Chemical compound CC(C)(C)OC(NC(CC1)(CCN1C(c1c(cc(cc2)N(CCC3)[C@H]3c3cc(F)ccc3F)[n]2nc1)=O)C(OC)=O)=O BWLVKCALZMJBLG-XMMPIXPASA-N 0.000 description 1
- WVMDSNGINQNHLN-UHFFFAOYSA-N CC(C)(C)OC(NOS(c1c(C)cc(C)cc1C)(=O)=O)=O Chemical compound CC(C)(C)OC(NOS(c1c(C)cc(C)cc1C)(=O)=O)=O WVMDSNGINQNHLN-UHFFFAOYSA-N 0.000 description 1
- KVHMZUCQVKSRCJ-LJQANCHMSA-N CC(C)(CO)NC(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O Chemical compound CC(C)(CO)NC(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O KVHMZUCQVKSRCJ-LJQANCHMSA-N 0.000 description 1
- BMCLFDMVDXJWQC-LJQANCHMSA-N CC(C1)(CN1C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O)O Chemical compound CC(C1)(CN1C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O)O BMCLFDMVDXJWQC-LJQANCHMSA-N 0.000 description 1
- ZEGLOZLEAGCDOC-RADWXHQJSA-N CCOC([C@H](CC1)CC[C@@H]1NC(c1c(c(F)c(cc2)N(CCC3)[C@H]3c3cc(F)ccc3F)[n]2nc1)=O)=O Chemical compound CCOC([C@H](CC1)CC[C@@H]1NC(c1c(c(F)c(cc2)N(CCC3)[C@H]3c3cc(F)ccc3F)[n]2nc1)=O)=O ZEGLOZLEAGCDOC-RADWXHQJSA-N 0.000 description 1
- BROGEJPOEZYWTH-VCUSLETLSA-N CCOC(c1c(CC(CC2)NC(c3c(cc(cc4)N(CCC5)[C@H]5c(cc(cc5)F)c5F)[n]4nc3)=O)[n]2nc1)=O Chemical compound CCOC(c1c(CC(CC2)NC(c3c(cc(cc4)N(CCC5)[C@H]5c(cc(cc5)F)c5F)[n]4nc3)=O)[n]2nc1)=O BROGEJPOEZYWTH-VCUSLETLSA-N 0.000 description 1
- JFNZLJVNEFTPQZ-HSZRJFAPSA-N CCOC(c1c(CN(CC2)C(c3c(cc(cc4)N(CCC5)[C@H]5c(cc(cc5)F)c5F)[n]4nc3)=O)[n]2nc1)=O Chemical compound CCOC(c1c(CN(CC2)C(c3c(cc(cc4)N(CCC5)[C@H]5c(cc(cc5)F)c5F)[n]4nc3)=O)[n]2nc1)=O JFNZLJVNEFTPQZ-HSZRJFAPSA-N 0.000 description 1
- YYLHTYNLZJFIMG-UHFFFAOYSA-N CCOC(c1c(c(F)c(cc2)N)[n]2nc1)=O Chemical compound CCOC(c1c(c(F)c(cc2)N)[n]2nc1)=O YYLHTYNLZJFIMG-UHFFFAOYSA-N 0.000 description 1
- QTAOYUQDRGXDQK-UHFFFAOYSA-N CCOC(c1c(cc(cc2)N(CCC3)C3c(cc(cc3)F)c3F)[n]2nc1)=O Chemical compound CCOC(c1c(cc(cc2)N(CCC3)C3c(cc(cc3)F)c3F)[n]2nc1)=O QTAOYUQDRGXDQK-UHFFFAOYSA-N 0.000 description 1
- QSGDEYILYSHSGH-VCUSLETLSA-N CCOC(c1c[n](CCC(C2)NC(c3c(cc(cc4)N(CCC5)[C@H]5c(cc(cc5)F)c5F)[n]4nc3)=O)c2n1)=O Chemical compound CCOC(c1c[n](CCC(C2)NC(c3c(cc(cc4)N(CCC5)[C@H]5c(cc(cc5)F)c5F)[n]4nc3)=O)c2n1)=O QSGDEYILYSHSGH-VCUSLETLSA-N 0.000 description 1
- VZBRNSPAFYUMPL-UHFFFAOYSA-N CC[O](C)(C)C(c1c[n](ccnc2)c2n1)=O Chemical compound CC[O](C)(C)C(c1c[n](ccnc2)c2n1)=O VZBRNSPAFYUMPL-UHFFFAOYSA-N 0.000 description 1
- XVAASTJGKSBBPU-UHFFFAOYSA-N CC[O](C)C(C(CCC1)CC1N)=O Chemical compound CC[O](C)C(C(CCC1)CC1N)=O XVAASTJGKSBBPU-UHFFFAOYSA-N 0.000 description 1
- LPRPWNKVZIDVLY-OAQYLSRUSA-N COC(C1(CCOCC1)NC(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O)=O Chemical compound COC(C1(CCOCC1)NC(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O)=O LPRPWNKVZIDVLY-OAQYLSRUSA-N 0.000 description 1
- YUQNLGCYIJJQMX-SFGWALBWSA-N COc(cc1)c([C@@H](CCC2)N2c(cc[n]2nc3)cc2c3C(N[C@H](CC2)CC[C@@H]2O)=O)cc1F Chemical compound COc(cc1)c([C@@H](CCC2)N2c(cc[n]2nc3)cc2c3C(N[C@H](CC2)CC[C@@H]2O)=O)cc1F YUQNLGCYIJJQMX-SFGWALBWSA-N 0.000 description 1
- RKZLUZDPGABBHH-GOSISDBHSA-N C[n]1nnc(CNC(c2c(cc(cc3)N(CCC4)[C@H]4c(cc(cc4)F)c4F)[n]3nc2)=O)n1 Chemical compound C[n]1nnc(CNC(c2c(cc(cc3)N(CCC4)[C@H]4c(cc(cc4)F)c4F)[n]3nc2)=O)n1 RKZLUZDPGABBHH-GOSISDBHSA-N 0.000 description 1
- SFXCPHLKTOKHGB-AYPBNUJASA-N C[n]1nnnc1[C@H](CC1)CC[C@@H]1NC(c1c(cc(cc2)N(CCC3)[C@H]3c3cc(F)cc(F)c3)[n]2nc1)=O Chemical compound C[n]1nnnc1[C@H](CC1)CC[C@@H]1NC(c1c(cc(cc2)N(CCC3)[C@H]3c3cc(F)cc(F)c3)[n]2nc1)=O SFXCPHLKTOKHGB-AYPBNUJASA-N 0.000 description 1
- TZURFTPUWZXSDS-HSZRJFAPSA-N Cc([o]c1c2)nc1ccc2NC(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O Chemical compound Cc([o]c1c2)nc1ccc2NC(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O TZURFTPUWZXSDS-HSZRJFAPSA-N 0.000 description 1
- PVJZBZSCGJAWNG-UHFFFAOYSA-N Cc(cc1C)cc(C)c1S(Cl)(=O)=O Chemical compound Cc(cc1C)cc(C)c1S(Cl)(=O)=O PVJZBZSCGJAWNG-UHFFFAOYSA-N 0.000 description 1
- CHKQALUEEULCPZ-UHFFFAOYSA-N Cc(cc1C)cc(C)c1S(ON)(=O)=O Chemical compound Cc(cc1C)cc(C)c1S(ON)(=O)=O CHKQALUEEULCPZ-UHFFFAOYSA-N 0.000 description 1
- ROSVOTFDPQNMJJ-GOSISDBHSA-N Cc1nnc(NC(c2c(cc(cc3)N(CCC4)[C@H]4c(cc(cc4)F)c4F)[n]3nc2)=O)[s]1 Chemical compound Cc1nnc(NC(c2c(cc(cc3)N(CCC4)[C@H]4c(cc(cc4)F)c4F)[n]3nc2)=O)[s]1 ROSVOTFDPQNMJJ-GOSISDBHSA-N 0.000 description 1
- JLYZYCPPKVDNQS-SNVBAGLBSA-N FC(Oc(cc1)cc([C@@H]2NCCC2)c1F)F Chemical compound FC(Oc(cc1)cc([C@@H]2NCCC2)c1F)F JLYZYCPPKVDNQS-SNVBAGLBSA-N 0.000 description 1
- ITGMTNOYOPHQAE-LJGSYFOKSA-N N[C@H](CC1)CC[C@@H]1C#N Chemical compound N[C@H](CC1)CC[C@@H]1C#N ITGMTNOYOPHQAE-LJGSYFOKSA-N 0.000 description 1
- UDPBBKMADGQOBX-IZLXSQMJSA-N N[C@H](CC1)CC[C@@H]1C(N)=O Chemical compound N[C@H](CC1)CC[C@@H]1C(N)=O UDPBBKMADGQOBX-IZLXSQMJSA-N 0.000 description 1
- MCKOYDSNCWNCHG-UHFFFAOYSA-N O=C(CCCCl)c1cc(F)ccc1F Chemical compound O=C(CCCCl)c1cc(F)ccc1F MCKOYDSNCWNCHG-UHFFFAOYSA-N 0.000 description 1
- KEASITVXHIRXIL-XAHWUOGOSA-N O=C(c1c(CC(C=C2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)N1C[C@H](CN2CCCC2)CCC1 Chemical compound O=C(c1c(CC(C=C2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)N1C[C@H](CN2CCCC2)CCC1 KEASITVXHIRXIL-XAHWUOGOSA-N 0.000 description 1
- HLFVUGRGYNZLGY-HXUWFJFHSA-N O=C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)N1CCNCC1 Chemical compound O=C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)N1CCNCC1 HLFVUGRGYNZLGY-HXUWFJFHSA-N 0.000 description 1
- MGSHZEQQZOIMIM-RUZDIDTESA-N O=C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)NC1(CN2CCCC2)CCOCC1 Chemical compound O=C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)NC1(CN2CCCC2)CCOCC1 MGSHZEQQZOIMIM-RUZDIDTESA-N 0.000 description 1
- QWZGSKZQEJFCFO-IRCUZVAFSA-N O=C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)NC1C[n]2nccc2CC1 Chemical compound O=C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)NC1C[n]2nccc2CC1 QWZGSKZQEJFCFO-IRCUZVAFSA-N 0.000 description 1
- SXZQKFOBJDFIMA-IVAFLUGOSA-N O=C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)NC1Cc2ncc[n]2CC1 Chemical compound O=C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)NC1Cc2ncc[n]2CC1 SXZQKFOBJDFIMA-IVAFLUGOSA-N 0.000 description 1
- OXCSAMDXGOZMHL-QNPDAYIESA-N O=C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)N[C@H](CC1)CC[C@@H]1/C(/I)=N/C=[IH] Chemical compound O=C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)N[C@H](CC1)CC[C@@H]1/C(/I)=N/C=[IH] OXCSAMDXGOZMHL-QNPDAYIESA-N 0.000 description 1
- ZNQRLIZDILVALE-JOCHJYFZSA-N O=C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)Nc(cc1)ncc1-[n]1ncnc1 Chemical compound O=C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)Nc(cc1)ncc1-[n]1ncnc1 ZNQRLIZDILVALE-JOCHJYFZSA-N 0.000 description 1
- HCURIBKYNFCEMI-OAQYLSRUSA-N O=C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)Nc1cnccc1 Chemical compound O=C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)Nc1cnccc1 HCURIBKYNFCEMI-OAQYLSRUSA-N 0.000 description 1
- UOLCFUGCLZLPNF-YBMSBYLISA-N OC(C(CC1)CN1C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O)=O Chemical compound OC(C(CC1)CN1C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O)=O UOLCFUGCLZLPNF-YBMSBYLISA-N 0.000 description 1
- QDZWDWDYGNIAPD-SGHZUCRHSA-N OC(C(CCC1)CC1NC(c1c(cc(cc2)N(CCC3)[C@H]3c3cc(F)ccc3F)[n]2nc1)=O)=O Chemical compound OC(C(CCC1)CC1NC(c1c(cc(cc2)N(CCC3)[C@H]3c3cc(F)ccc3F)[n]2nc1)=O)=O QDZWDWDYGNIAPD-SGHZUCRHSA-N 0.000 description 1
- RSJMSYMWNWQBNU-HXUWFJFHSA-N OC(C1(CCOCC1)NC(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O)=O Chemical compound OC(C1(CCOCC1)NC(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O)=O RSJMSYMWNWQBNU-HXUWFJFHSA-N 0.000 description 1
- OBYTUXALJHGXKI-RUZDIDTESA-N OC(C1)CN1c(cc1)ccc1NC(c1c(cc(cc2)N(CCC3)[C@H]3c3cc(F)ccc3F)[n]2nc1)=O Chemical compound OC(C1)CN1c(cc1)ccc1NC(c1c(cc(cc2)N(CCC3)[C@H]3c3cc(F)ccc3F)[n]2nc1)=O OBYTUXALJHGXKI-RUZDIDTESA-N 0.000 description 1
- ZJHIMKCYZBOHEC-AKCHCHLHSA-N OC([C@H](CC1)CC[C@@H]1NC(c1c(c(F)c(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O)=O Chemical compound OC([C@H](CC1)CC[C@@H]1NC(c1c(c(F)c(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O)=O ZJHIMKCYZBOHEC-AKCHCHLHSA-N 0.000 description 1
- BTOOYWLEENDCSR-VXNXSFHZSA-N OC(c1c(CC(CC2)NC(c3c(cc(cc4)N(CCC5)[C@H]5c(cc(cc5)F)c5F)[n]4nc3)=O)[n]2nc1)=O Chemical compound OC(c1c(CC(CC2)NC(c3c(cc(cc4)N(CCC5)[C@H]5c(cc(cc5)F)c5F)[n]4nc3)=O)[n]2nc1)=O BTOOYWLEENDCSR-VXNXSFHZSA-N 0.000 description 1
- JUJWYZYHAFCIRA-OAQYLSRUSA-N OC(c1c(CN(CC2)C(c3c(cc(cc4)N(CCC5)[C@H]5c(cc(cc5)F)c5F)[n]4nc3)=O)[n]2nc1)=O Chemical compound OC(c1c(CN(CC2)C(c3c(cc(cc4)N(CCC5)[C@H]5c(cc(cc5)F)c5F)[n]4nc3)=O)[n]2nc1)=O JUJWYZYHAFCIRA-OAQYLSRUSA-N 0.000 description 1
- WGGWLQADJPVAPS-MRXNPFEDSA-N OC(c1c(cc(cc2)N(CCC3)[C@H]3c3cc(F)cc(F)c3)[n]2nc1)=O Chemical compound OC(c1c(cc(cc2)N(CCC3)[C@H]3c3cc(F)cc(F)c3)[n]2nc1)=O WGGWLQADJPVAPS-MRXNPFEDSA-N 0.000 description 1
- ZLAYPTVDFWJZMX-VXNXSFHZSA-N OC(c1c[n](CCC(C2)NC(c3c(cc(cc4)N(CCC5)[C@H]5c(cc(cc5)F)c5F)[n]4nc3)=O)c2n1)=O Chemical compound OC(c1c[n](CCC(C2)NC(c3c(cc(cc4)N(CCC5)[C@H]5c(cc(cc5)F)c5F)[n]4nc3)=O)c2n1)=O ZLAYPTVDFWJZMX-VXNXSFHZSA-N 0.000 description 1
- KHQGUMDHPXSGDK-WRVMZKTCSA-N OCC(CC1)(CCC1NC(c1c(cc(cc2)N(CCC3)[C@H]3c3cc(F)cc(F)c3)[n]2nc1)=O)O Chemical compound OCC(CC1)(CCC1NC(c1c(cc(cc2)N(CCC3)[C@H]3c3cc(F)cc(F)c3)[n]2nc1)=O)O KHQGUMDHPXSGDK-WRVMZKTCSA-N 0.000 description 1
- KUIPTAUSCZJJJD-GOSISDBHSA-N OCCNC(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O Chemical compound OCCNC(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O KUIPTAUSCZJJJD-GOSISDBHSA-N 0.000 description 1
- QFQXFUCCAUZBRA-KSFYIVLOSA-N OC[C@@H](CCC1)CN1C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O Chemical compound OC[C@@H](CCC1)CN1C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O QFQXFUCCAUZBRA-KSFYIVLOSA-N 0.000 description 1
- QFQXFUCCAUZBRA-OPAMFIHVSA-N OC[C@H](CCC1)CN1C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O Chemical compound OC[C@H](CCC1)CN1C(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O QFQXFUCCAUZBRA-OPAMFIHVSA-N 0.000 description 1
- BOZPXXFHLVBUPW-HNAYVOBHSA-N OC[C@H](CNC(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O)O Chemical compound OC[C@H](CNC(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O)O BOZPXXFHLVBUPW-HNAYVOBHSA-N 0.000 description 1
- RBSJLOIXJBNNJB-KBXCAEBGSA-N O[C@@H](CC1)CN1C(c1c(c(F)c(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O Chemical compound O[C@@H](CC1)CN1C(c1c(c(F)c(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O RBSJLOIXJBNNJB-KBXCAEBGSA-N 0.000 description 1
- MJHCPCJURMMLCL-RADWXHQJSA-N O[C@H](CC1)CC[C@@H]1NC(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O Chemical compound O[C@H](CC1)CC[C@@H]1NC(c1c(cc(cc2)N(CCC3)[C@H]3c(cc(cc3)F)c3F)[n]2nc1)=O MJHCPCJURMMLCL-RADWXHQJSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present application relates to a series of substituted pyrazolo[l,5-a]pyridine compounds.
- the present application is further directed to use such compounds as tropomyosin receptor kinase (Trk) family protein kinase inhibitors.
- the present application also describes method of making such compounds and pharmaceutical compositions comprising such compounds.
- TrkA, TrkB and TrkC which make up the Trk receptor family, are high affinity receptor tyrosine kinases activated by a group of soluble growth factors called neurotrophins (NT) (Curr Opin Neurobiol, 2001, 11, 272-280). Trks play important roles in pain sensation, tumour cell growth and survival signaling (Expert Opin. Ther. Patents, 2009, 19(3):305-319).
- NT neurotrophins
- Inhibitors of the Trk/neurotrophin pathway have been demonstrated to be effective in numerous animal models of pain. For example, sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain (Bone, 2011, 48(2), 389-398).
- Administration of NGF receptor (TrkA) inhibitor K252a showed significant suppression of mechanical hyperalgesia (relevant to the pathogenesis of myofascial pain syndrome (MPS) in animal models (J. Pain, Article in Press, 2011, 12(10), 1059-1068).
- Antagonistic NGF and TrkA antibodies have been shown to be efficacious in inflammatory and neuropathic pain animal models (Neuroscience, 1994, 62,327-331; J.
- TrkA located on peripheral pain fibers. It has also been demonstrated in various tumor models in both mice and rats that neutralizing NGF with a monoclonal antibody inhibits cancer related pain. Further, activation of the BDNF/TrkB pathway has been implicated in numerous studies as a modulator of various types of pain including inflammatory pain (J. Physiol. 2005, 569:685-95), neuropathic pain (Proc. Natl. Acad. Sci. USA 1999, 96:7714-18) and surgical pain (Molecular Pain, 2008, 4(28), 1-11). Since TrkA kinases have been demonstrated to serve as a mediator of NGF driven biological responses, inhibitors of TrkA and/or other Trk kinases may provide an effective treatment for various pain conditions.
- Trk A, B and C have been shown to be effective in treatment of pre-clinical models of inflammatory diseases such as asthma (Pharmacol. Therapeut., 2008, 117(1), 52-76), interstitial cystitis (J. Urology, 2005, 173(3), 1016-21), inflammatory bowel diseases including ulcerative colitis and Crohn's disease (Gut, 2000, 46(5), 670-678) and inflammatory skin diseases such as atopic dermatitis (Arc Dermatol Res., 2006, 298(1), 31-37), eczema and psoriasis (J. Investig Dermatol, 2004, 122(3), 812-819).
- inflammatory diseases such as asthma (Pharmacol. Therapeut., 2008, 117(1), 52-76), interstitial cystitis (J. Urology, 2005, 173(3), 1016-21), inflammatory bowel diseases including ulcerative colitis and Crohn's disease (Gut, 2000, 46(5), 670-67
- the current treatment regimes for pain conditions utilize several classes of compounds.
- the opiates apart from being potentially addictive have several adverse effects such as emesis, constipation, dose-related respiratory depression.
- Nonsteroidal anti- inflammatory analgesics (NSAID) also have drawbacks such as gastric ulceration, dyspepsia and insufficient efficacy in treating severe pain. Accordingly, there is a continuing need for new and more effective treatments for the relief of pain, especially chronic pain.
- NSAID nonsteroidal anti- inflammatory analgesics
- JP Publication No. 2003231687 describes a series of pyrazolyl condensed cyclic compounds as Trk inhibitors.
- PCT Publication No. 200505427 describes compounds containing a 1,4,5,6- tetrahydropyrrolo[3,4-c]pyrazole bicyclic scaffold as TrkA inhibitors.
- PCT Publication No. 2004011461 describes a series of isothiazole derivatives as Trk inhibitors.
- R 1 is independently selected from hydrogen, alkyl, halogen, alkoxy or haloalkoxy;
- R 2 is selected from hydrogen or fluorine
- R when R is hydrogen, R is -NR R ; and when R is fluorine, R is -NR R or -OR x wherein R x is hydrogen or alkyl;
- R is hydrogen, alkyl, hydroxyalkyl or alkoxyalkyl
- R 4 is selected from
- R 3 and R 4 together with the nitrogen atom to which they are attached form an optionally susbstituted 3-10 membered heterocyclic ring wherein the optional substituent is selected from hydroxy, cyano, halogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, COOR b , -CONR c R d , -NR e R f , -COR g , -0(CH 2 ) 0 -OR h , -S0 2 R ⁇ -(CHR j ) p -R 5 or heterocyclyl optionally substituted with hydroxyl or alkyl;
- R 5 is independently selected from an optionally substituted group selected from cycloalkyl, aryl, heterocyclyl; wherein the optional substituent is hydroxyl, alkyl, haloalkyl or S0 2 R g ;
- R b is independently selected from hydrogen or alkyl
- R c is independently selected from hydrogen or alkyl
- R d is independently selected from hydrogen, alkyl or alkoxy
- R e is independently selected from hydrogen, alkyl or hydroxyalkyl
- R is independently selected from hydrogen or alkyl
- R e and R f in each occurrence, independent of each other, together with the nitrogen atom to which they are attached form optionally substituted 3-6 membered heterocyclic ring, wherein the optional substituent is selected from hydroxyl, alkyl, acyl, mesyl or COOR b ;
- R g is independently selected from alkyl, aryl, heterocyclyl or -NR e R f ;
- R h is independently represents alkyl
- R 1 is independently selected from alkyl, aryl or -NR e R d ;
- R J is independently selected from hydrogen or alkyl
- R y is independently selected from hydrogen, hydroxy, hydroxyalkyl, alkyl or aryl;
- R z is independently selected from hydrogen or alkyl
- n is independently selected from 1, 2, 3 or 4;
- p 0, 1, 2, 3 or 4.
- the present application further relates to methods of treating or preventing conditions, diseases and/or disorders associated with abnormal or deregulated Trk kinase activity by administereing effective amount of a compound of formula (I), to a patient in need thereof.
- One aspect of the present application provides methods of treating or preventing conditions, diseases and/or disorders associated with abnormal or deregulated TrkA kinase activity by administereing effective amount of a compound of formula (I), to a patient in need thereof.
- Trk kinase activity such as pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, fibrosis, neurodegenerative disease or a disease, disorder or injury relating to dysmyelination or demyelination by administering a therapeutically effective amount of compound of formula (I), to a patient in need thereof.
- Trk kinase activity such as pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, fibrosis, neurodegenerative disease or a disease, disorder or injury relating to dysmyelination or demyelination by administering a therapeutically effective amount of compound of formula (I),
- the present application also relates to pharmaceutical compositions comprising effective amount of a compound of formula (I), and a pharmaceutically acceptable carrier or diluent, and the use of such compositions in the treatment and/or prevention of diseases associated with inhibiting TrkA in a patient in need thereof, such as pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, fibrosis, neurodegenerative disease, a disease, disorder, or injury relating to dysmyelination or demyelination or certain infectious diseases such as Trypanosoma cruzi infection
- Halo' represents fluorine, chlorine, bromine, or iodine.
- 'Alkyl' group refers to linear or branched alkyl group with 1 to 10 carbon atoms.
- Exemplary alkyl group includes, but is not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, hexyl, heptyl, octyl and the like.
- 'Hydroxyalkyl' means at least one hydrogen atom of an alkyl group is replaced by a hydroxyl group.
- Alkyl group is as defined above.
- hydroxyalkyl groups include one or more of, but are not limited to hydroxymethyl, hydroxyethyl and the like. Unless otherwise specified, a hydroxyalkyl group typically has from 1 to 10 carbon atoms and 1 to 3 hydroxyl groups.
- 'Haloalkyl' means at least one halogen atom is substituted on an alkyl group. Both halogen and alkyl have the meaning as defined above.
- Representative examples of haloalkyl groups include, but are not limited to, fluoromethyl, chloromethyl, fluoroethyl, chloroethyl, difluoromethyl, trifluoromethyl, dichloroethyl, trichloroethyl and the like. Unless otherwise specified, a haloalkyl group typically has from 1 to 10 carbon atoms and 1 to 5 halogen atoms.
- alkoxy' group refers to an -O(alkyl) group, wherein alkyl group is as defined above.
- alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n- butoxy, iso-butoxy, t-butoxy, and the like. Unless otherwise specified, an alkoxy group has from 1 to 10 carbon atoms.
- Alkoxyalkyl' refers to an alkyl group substituted with atleast one alkoxy group, wherein alkoxy and alkyl groups are as defined above.
- the alkoxy group can have from 1 to 10 carbon atoms, and the alkyl group can have up to 10 carbon atoms.
- Exemplary alkoxyalkyl groups include, but are not limited to, ethoxymethyl, propoxyethyl, ethoxybutyl and the like.
- 'Aryl' is a monocyclic or polycyclic aromatic ring system.
- exemplary aryl groups include, but are not limited to, phenyl, naphthyl, and the like. Unless otherwise specified, an aryl group typically has from 6 to about 14 carbon atoms but the invention is not limited in that respect.
- 'Cycloalkyl' group refers to a cyclic alkyl group which may be mono, bicyclic, polycyclic, or a fused/bridged ring system.
- exemplary cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.
- a cycloalkyl group typically has from 3 to about 10 carbon atoms.
- Typical bridged cycloalkyls include, but are not limited to adamantyl, noradamantyl, bicyclo[ 1.1.0]butanyl, norbornyl(bicyclo[2.2.1 Jheptanyl), and the like.
- 'Haloalkoxy means at least one halogen atom is substituted on an alkoxy group, wherein alkoxy and halogen groups are as defined above.
- exemplary haloalkoxy groups include, but not limited to, fluoromethoxy, chloromethoxy, trifluoromethoxy, trichloroethoxy, fluoroethoxy, chloroethoxy, trifloroethoxy, perfluoroethoxy (-OCF 2 CF3), trifluoro-t-butoxy, hexafluoro-t-butoxy, perfluoro-t-butoxy (-OC(CF 3 ) 3 ), and the like.
- an haloalkoxy group typically has from 1 to 10 carbon atoms and 1 to 5 halogen atoms.
- 'Heterocyclyl'or 'Heterocyclic' or 'Heterocycle' is a monocyclic or poly cyclic ring system, saturated or unsaturated or aromatic; having at least one heteroatom or heterogroup selected from -0-, -N-, -S-, -SO, -S0 2 , or -CO.
- Exemplary saturated heterocyclyl ring groups include, but not limited to, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, morpholinyl, thiomorpholinyl, thiomorpho line- 1,1 -dioxide, tetrahydro-2H-thiopyranyl, thiazolidinyl, 1,3-dioxolanyl, 1,4- dioxanyl, 1 -oxidotetrahydro-2H-thiopyranyl, 1 , 1 -dioxidotetrahydro-2H-thiopyranyl, hexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, azepanyl and the like. Unless otherwise specified, a heterocyclyl
- Exemplary unsaturated heterocyclyl ring groups, aromatic or non-aromatic rings include, but not limited to, furanyl, oxazolyl, isoxazole, imidazolyl, triazolyl, thiazolyl, pyridinyl, thiazinyl, pyrazinyl, pyrazolyl, tetrazolyl, imidazothiazolyl, furanyl, oxazolyl, isoxazole, imidazolyl, oxadiazolyl, triazolyl, thiazolyl, pyridinyl, thiazinyl, pyrazinyl, pyrazolyl, tetrazolyl, imidazothiazolyl, indolizidinyl, indolyl, oxoindolyl, quinolinyl, 3,4- dihydroisoquinolin-2(lH)-yl, quinoxalinyl, benzoxazolyl,
- heterocyclic ring' refers to a monocyclic or poly eye lie ring system, saturated or unsaturated or aromatic; containing one nitrogen atom and optionally 1-3 additional heteroatoms or heterogroups independently selected from O, S, N, CO, SO, or S0 2 .
- Exemplary 3-10 membered heterocyclic rings include (5,6-dihydroimidazo[l,2- a]pyrazin-7(8H)-yl), 5,6,7,8-tetrahydroimidazo[l ,2-a]pyrazine-7-yl, 5,6-dihydro- [l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl, lH-l,2,4-triazol-l-yl; dihydroisoquinolin-2(lH)-yl, 4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazine-5-yl, pyrrolidin-l-yl; azetidin-l-yl, piperidin- 1-yl;, piperazin-l-yl, (Hexahydro-lH-pyrido [1, 2-a] pyrazin-2(6H)-yl), (Hexahydropyr
- '3-6 membered heterocyclic ring' refers to a monocyclic saturated ring system, containing one nitrogen atom and optionally 1-3 additional heteroatoms or heterogroups independently selected from O, S, N, CO, SO, or S0 2 .
- exemplary 3-6 membered heterocyclic rings include pyrrolidinyl, azetidinyl and the like.
- the Trk's are made up of three family members TrkA, TrkB and TrkC that bind to and mediate the the signal transduction derived from the Neurotrophins. Inhibitors of the Trk/neutrophin pathway have been demonstrated to be highly effective in numerous preclinical animal models of pain.
- the compounds of the invention are modulators of the Trk receptors, particularly TrkA.
- TrkA refers to one of Trk's high affinity binding protein kinase receptors that are activated by Neurotrophins (NT), a group of soluble growth factors Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin 3-5 (NT 3-5).
- NT Neurotrophins
- NGF Nerve Growth Factor
- BDNF Brain-Derived Neurotrophic Factor
- NT 3-5 Neurotrophin 3-5
- Optionally substituted' means that the substitution is optional and therefore it is possible for the designated atom or group to be unsubstituted.
- substitution means that any number of hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the normal valence of the designated atom is not exceeded, and that the substitution results in a stable compound.
- two hydrogens on the atom are replaced and when the substitution is fluoro, then one hydrogen on the atom is replaced and the like.
- the chosen substituents are independent of each other (i.e same or different).
- the term 'subject' or 'patient' means mammals, such as humans and other animals, including horses, dogs, cats, rats, mice, sheep, pigs, monkeys, chimpanzees or other apes or primates.
- the subject may include subjects for which treatment and/or prevention of the conditions described herein would be beneficial.
- a 'therapeutically effective amount' is the amount of compound of the present application that is effective in generating biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease.
- the term 'a therapeutically effective amount' refers to the amount of the compound of the present application that, when administered to a subject, is effective in (i) at least partially alleviating, inhibiting, preventing and/or ameliorating a condition, or a disorder or a disease mediated by TrkA, TrkB and/or TrkC, associated with TrkA, TrkB and/or TrkC activity or characterized by activity (normal or abnormal) of TrkA, TrkB and/or TrkC; (ii) reducing or inhibiting the activity of TrkA, TrkB and/or TrkC; or (iii) reducing or inhibiting the expression of TrkA, TrkB and/or TrkC.
- a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of TrkA, TrkB and/or TrkC; or at least partially reducing or inhibiting the expression of TrkA, TrkB and/or TrkC.
- the terms 'treating' or 'to treat' means to alleviate symptoms, eliminate the causation either on a temporary or permanent basis, or to prevent or slow the appearance of symptoms.
- the term 'treatment' includes alleviation, elimination of causation of or prevention of any of the diseases or disorders described above.
- the compounds described herein are typically administered in admixture with one or more pharmaceutically acceptable excipients or carriers in the form of a pharmaceutical composition.
- a 'composition' may contain one compound or a mixture of compounds.
- a 'pharmaceutical composition' is any composition useful in producing at least one physiological response in a subject to which such pharmaceutical composition is administered.
- substantially pure means that the isolated material is at least 80% pure, preferably 90% pure, more preferably 95% pure, and even more preferably 99% pure as measured by a suitable analytical techniques known in the art.
- One or more compounds of formula (I) can be supplied in the form of a therapeutic composition that is within the scope of the present application.
- the term 'Pharmaceutically acceptable salts' refers to any acid or base salt, pharmaceutically acceptable solvates, or any complex of the compound that, when administered to a recipient, is capable of providing (directly or indirectly) a compound as described herein. It should be appreciated, however, that salts that are not pharmaceutically acceptable also lie within the scope of the application. The preparation of salts can be carried out using known methods.
- salts of compound of formula (I)contemplated refers to salts prepared from acids or bases including inorganic or organic acids and inorganic or organic bases by conventional chemical methods using a compound of formula (I).
- such salts may be prepared, for example, by making free base of the compounds and reacting with a stoichiometric quantity of the appropriate acid and vice-versa in water or in an organic solvent, or in a mixture of the two.
- the comounds of the present applications may form mono, di or tris salts.
- salts may be prepared from acids, including inorganic or organic acids (acid addition salts).
- acids include, but not limited toformic, acetic, trifluoroacetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, stearic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic),nitric, hydrochloride, hydrobromide, isoethionic, hydroiodide, phosphoric, sulfuric, succinic, tartaric, methanesulfonic, ethanesulfonic, benzenesulfonic, benzoic, mucic, pantothenic, p-toluenesulf
- Salts formed from inorganic bases include sodium, potassium, lithium, calcium, copper, magnesium, manganic salts, manganous, zinc, aluminum, ammonium, ferric, ferrous and the like.
- Salts derived from organic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N- dibenzylethylene-diamine s diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylgiucamine, morpholine, piperazine, piperid e, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
- stereoisomers is a general term used for all isomers of an individual molecule that differ only in the orientation of their atoms in space. Where the compounds according to the present application possess one or more asymmetric centers and compounds with asymmetric centers give rise to enantiomers, diastereomers or both as pure or partially purified compounds. It is to be understood that all stereoisomeric forms of the compounds of the invention, including but not limited to, diastereomers, enantiomers and atropsiomers, as well as mixtures thereof such as forms, are included in the scope of the present application. Preparation of such stereoisomeric forms of compound of formula (I), may be achieved by appropriate modification of the methodology known in the art.
- racemic mixtures of the compound of formula (I) may be separated to isolate individual enantiomers or diastereomers. Such separation can be carried out by methods known in the art, such as the coupling of a racemic mixture of compound of formula (I) to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography.
- the coupling reaction is often the formation of salts using an enantiomerically pure acid or base.
- the diastereomeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue.
- racemic mixture of the compounds can also be separated directly by chromatographic methods using chiral stationary phases, which methods are well known in the art.
- any enantiomer or diastereomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or known reagents.
- stereochemistry for any particular compound disclosed herein, wherein the stereochemistry of any particular chiral atom is not specified, then all stereoisomers are contemplated and included as the compounds of the application. Where stereochemistry is specified by a solid wedge or a dashed wedge bond or dashed line representing a particular configuration then that stereoisomer is so specified and defined. Following the standard chemical literature description practice and as used herein, a full wedge bond means above the ring plane, and a dashed wedge bond or dashed line means below the ring plane.
- Pharmaceutically acceptable solvates of compound of formula (I) may be hydrates or comprising other solvents of crystallization such as alcohols.
- Pharmaceutically acceptable solvates of compound of formula (I) may be prepared by conventional methods such as dissolving the compounds of formula (I) in solvents such as water, methanol, ethanol etc., preferably water and recrystallizing by using different crystallization techniques.
- a bond to a substituent and/or a bond that links a molecular fragment to the remainder of a compound may be shown as intersecting one or more bonds in a ring structure. This indicates that the bond may be attached to any one of the atoms that constitutes the ring structure, so long as a hydrogen atom could otherwise be present at that atom. Where no particular substituent(s) is identified for a particular position in a structure, then hydrogen(s) is present at that position.
- R 1 is independently selected from hydrogen, alkyl, halogen, alkoxy or haloalkoxy;
- R 2 is selected from hydrogen or fluorine;
- R when R is hydrogen, R is -NR R ; and when R is fluorine, R is -NR R or -OR x wherein R x is hydrogen or alkyl;
- R 3 is hydrogen, alkyl, hydroxyalkyl or alkoxyalkyl
- R 4 is selected from
- R 4 can alternatively be hydroxyalkyl Alternatively R 3 and R 4 together with the nitrogen atom to which they are attached form an optionally susbstituted 3-10 membered heterocyclic ring wherein the optional substituent is selected from hydroxy, cyano, halogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, COOR b , -CONR c R d , -NR e R f , -COR g , -0(CH 2 ) 0 -OR h , -S0 2 R -(CHR j ) p -R 5 or heterocyclyl optionally substituted with hydroxyl or al
- R 5 is independently selected from an optionally substituted group selected from cycloalkyl, aryl, heterocyclyl; wherein the optional substituent is hydroxyl, alkyl, haloalkyl or S0 2 R g ;
- R b is independently selected from hydrogen or alkyl
- R c is independently selected from hydrogen or alkyl
- R d is independently selected from hydrogen, alkyl or alkoxy
- R e is independently selected from hydrogen, alkyl or hydroxyalkyl
- R is independently selected from hydrogen or alkyl
- R e and R f in each occurrence, independent of each other, together with the nitrogen atom to which they are attached form optionally substituted 3-6 membered heterocyclic ring, wherein the optional substituent is selected from hydroxyl, alkyl, acyl, mesyl or COOR b ;
- R g is independently selected from alkyl, aryl, heterocyclyl or -NR e R f ;
- R h is independently represents alkyl
- R 1 is independently selected from alkyl, aryl or -NR e R d ;
- R J is independently selected from hydrogen or alkyl
- R y is independently selected from hydrogen, hydroxy, hydroxyalkyl, alkyl or aryl; R z is independently selected from hydrogen or alkyl;
- n is independently selected from 0, 1, 2, 3 or 4;
- n is independently selected from 1, 2, 3 or 4;
- p 0, 1, 2, 3 or 4.
- the compounds of formula (I) can also exist in the form of pharmaceutically acceptable salts, pharmaceutically acceptable solvates or stereoisomers thereof
- the present application relates to the compounds of formula (I), which are inhibitrs of TrkA, TrkB and/or TrkC kinase activity, for the treatment or prevention of diseases or conditions or disorders associated with TrkA, TrkB and/or TrkC kinase activity.
- One embodiment of the present application further provides methods of treating or preventing conditions, diseases and/or disorders associated TrkA, TrkB and/or TrkC kinase activity, wherein the method includes administration of a therapeutically effective amount of a compound formula (I), to a patient in need thereof.
- Trk kinase activity such as pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, , psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, fibrosis, neurodegenerative; a disease, disorder or injury relating to dysmyelination or demyelination or infectious diseases such as Trypanosoma cruzi infection by administering a therapeutically effective amount of compound of formula (I), to a patient in need thereof.
- Trk kinase activity such as pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, , psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, fibrosis, neurodegenerative
- One embodiment of the present application further provides methods of treating or preventing conditions, diseases and/or disorders associated TrkA, wherein the method includes administration of a therapeutically effective amount of a compound formula (I), to a patient in need thereof.
- the method includes administration of a therapeutically effective amount of a compound formula (I), to a patient in need thereof.
- a method of treating or preventing pain or pain disorder in a patient in need of such a treatment comprising the administration of a therapeutically effective amount of the compound of formula (I), to said patient.
- pain includes chronic and acute pain but is not limited to, pain related to cancer, surgery, bone fracture, skeletal pain caused by tumor metastasis, osteoarthritis, psoriatic arthritis, rheumatoid arthritis, interstitial cystitits, chronic pancreatitis, visceral pain, inflammatory pain, migraine, chronic lower back pain, bladder pain syndrome and neuropathic pain.
- a method of binding TrkA protein in a patient in need of such a treatment comprising the administration of a therapeutically effective amount of the compound of formula (I) to said patient.
- the present application further relates to use of compound of formula (I) for treating or preventing conditions, diseases and/or disorders associated with abnormal or deregulated Trk kinase activity.
- One aspect of the present application provides use of compound of formula (I) for treating or preventing conditions, diseases and/or disorders associated with abnormal or deregulated TrkA kinase activity, in a patient in need thereof.
- an use of the compound for formula (I) for treating or preventing pain or pain disorder in a patient in need of such a treatment comprising the administration of a therapeutically effective amount of the compound of formula (I), to said patient.
- pain includes chronic and acute pain but is not limited to, pain related to cancer, surgery, bone fracture, skeletal pain caused by tumor metastasis, osteoarthritis, visceral pain, inflammatory pain and neuropathic pain.
- the compounds of the present application may be useful for the pain disorders include neuropathic pain (such as postherpetic neuralgia, nerve injury, the "dynias", e.g., vulvodynia, phantom limb pain, root avulsions, painful diabetic neuropathy, painful traumatic mononeuropathy, painful polyneuropathy); central pain syndromes (potentially caused by virtually any lesion at any level of the nervous system); postsurgical pain syndromes (eg, postmastectomy syndrome, postthoracotomy syndrome, stump pain); bone and joint pain (osteoarthritis), repetitive motion pain, denial pain, cancer pain, myofascial pain (muscular injury, fibromyalgia); perioperative pain (general surgery, gynecological), chronic pain, dysmenorrhea, as well as pain associated with angina, and inflammatory pain of varied origins (e.g.
- neuropathic pain such as postherpetic neuralgia, nerve injury, the "d
- osteoarthritis rheumatoid arthritis, rheumatic disease, teno- synovitis and gout
- headache migraine and cluster headache, headache, primary hyperalgesia, secondary hyperalgesia, primary allodynia, secondary allodynia, or other pain caused by central sensitization.
- a method of treating or preventing pain which comprises administering to said subject a pharmaceutical composition comprising an effective amount of a compound of formula (I).
- compositions in the treatment and/or prevention of diseases associated with inhibition of TrkA, such as pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, neurodegenerative disease, a disease, disorder, or injury relating to dysmyelination or demyelination or certain infectious diseases such as Trypanosoma crurzi infection.
- diseases associated with inhibition of TrkA such as pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, neurodegenerative disease, a disease, disorder, or injury relating to dysmyelination or demyelination or certain infectious diseases such as Trypanosoma crurzi infection.
- the compounds of formula (I) are useful in treating or preventing neurodegenerative disease.
- neurodegenerative disease is Parkinson's disease or
- the present application provides a method of treating or preventing neurodegenerative disease.
- neurodegenerative disease as described above, is Parkinson's disease or Alzheimer's disease.
- the present application provides method of treating or preventing certain infectious diseases, for example Trypanosoma cruzi infection, by administering effective amount of compound of formula (I) to a patient in need thereof.
- certain infectious diseases for example Trypanosoma cruzi infection
- the present application provides method of treating or preventing Trypanosoma cruzi infection by administering effective amount of compound of formula (I), to a patient in need thereof.
- a pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of formula (I) and pharmaceutically acceptable carrier.
- TrkA inhibitors in a subject which comprises administering to said subject (i.e., a patient) a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I).
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I).
- the term "subject” and “patient” can be the same and can be used interchangeably.
- a method of inhibiting TrkA comprising administering to said subject a pharmaceutical composition comprising an effective amount of a compound of formula (I).
- a method of treating or preventing pain or pain disorder in a patient in need of such a treatment comprising the administration of a therapeutically effective amount of the compound of formula (I) enlisted in List-1, or a stereoisomer thereof or a pharmaceutically acceptable salt thereof to said patient.
- the present application further relates to methods of treating a patient for diseases or disorders in which the nerve growth factor (NGF) receptor are involved, in particular TrkA, such as such as pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder, or injury relating to dysmyelination or demyelination, by administering a therapeutically effective amount of compound of formula (I), as enlisted in List-1, to said patient.
- NGF nerve growth factor
- a method of treating or preventing pain or pain disorder in a patient in need of such a treatment comprising the administration of a therapeutically effective amount of the compound of formula (I), as enlisted in List-1, to said patient.
- pain includes chronic and acute pain but is not limited to, pain related to cancer, surgery, bone fracture, skeletal pain caused by tumor metastasis, osteoarthritis, visceral pain, inflammatory pain and neuropathic pain.
- a method of binding NGF receptor TrkA protein in a patient in need of such a treatment comprising the administration of a therapeutically effective amount of the compound of formula (I), as enlisted in List-1, to said patient.
- the present application further relates to use of compound of formulation (I) for treating a patient for diseases or disorders in which the NGF receptor are involved, in particular TrkA, such as such as pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder, or injury relating to dysmyelination or demyelination, by administering a therapeutically effective amount of compound of formula (I), as enlisted in List- 1 , to said patient.
- TrkA such as such as pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder, or injury relating to dysmyelination or demyelination
- an use of the compound for formula (I) for treating or preventing pain or pain disorder in a patient in need of such a treatment comprising the administration of a therapeutically effective amount of the compound of formula (I), as enlisted in List-1, to said patient.
- pain includes chronic and acute pain but is not limited to, pain related to cancer, surgery, bone fracture, skeletal pain caused by tumor metastasis, osteoarthritis, visceral pain, inflammatory pain and neuropathic pain.
- a method of treating or preventing pain which comprises administering to said subject a pharmaceutical composition comprising an effective amount of a compound of formula (I), as enlisted in List-1.
- compositions in the treatment or prevention of diseases associated with inhibiting NGF receptor TrkA, such as pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder, or injury relating to dysmyelination or demyelination.
- diseases associated with inhibiting NGF receptor TrkA such as pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder, or injury relating to dysmyelination or demyelination.
- the pharmaceutical composition of a compound of formula (I) may be administered enterally and/or parenterally.
- Parenteral administration includes subcutaneous, intramuscular, intradermal, intramammary, intravenous, and other administrative methods known in the art.
- Enteral administration includes solution, tablets, sustained release capsules, enteric coated capsules, syrups, beverages, foods, and other nutritional supplements.
- the present pharmaceutical compositions may be at or near body temperature. In some embodiments, the present pharmaceutical compositions may be below body temperatures. In other embodiments, the present pharmaceutical compositions may be above body temperatures.
- the compounds of the present invention may be administered in a wide variety of different dosage forms.
- they may be combined with various pharmaceutically acceptable inert carriers in the form of, but not limited to, tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like.
- Such carriers may include solid diluents or fillers, sterile aqueous media, and various nontoxic organic solvents, etc.
- oral pharmaceutical compositions may be sweetened and/or flavored.
- the compounds of the invention may be present in such dosage forms at concentration levels ranging from about 0.1 % to about 90% by weight.
- compounds of the present invention for treatment may be administered to a subject in a suitable effective dose in the range of from about 0.01 to about 100 mg per kilogram of body weight of recipient per day, in some embodiments, in the range of from about 0.5 to about 50 mg per kilogram body weight of recipient per day, in still other embodiments, in the range of from about 0.1 to about 20 mg per kilogram body weight of recipient per day.
- the exemplary dose may be suitably administered once daily, or several sub-doses, e.g. 2 to 5 sub-doses, may be administered at appropriate intervals through the day, or on other appropriate schedules.
- An embodiment of the present invention provides the preparation of compounds of formula (I) according to the procedures of the following examples, using appropriate materials. Those skilled in the art will understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. Moreover, by utilizing the procedures described in detail, one of ordinary skill in the art can prepare additional compounds of the present invention claimed herein. All temperatures are in degrees Celsius (°C) unless otherwise noted.
- ACN (Acetonitrile), BINAP (2,2 * -bis(diphenylphosphino)-l,r-binaphthyl), CDC1 3 (Deuterated chloroform), CHC1 3 (Chloroform), CD 3 OD (Deuterated methanol), Cs 2 C0 3 (Caesium Carbonate) DCM (Dichloromethane), DCE (Dichloroethene), DIPEA [(N,N- diisopropylethylamine) (Hunig's base)], DMF ( ⁇ , ⁇ -dimethylformamide), DMSO (Dimethyl sulfoxide), DMAP (Dimethyl amino pyridine), EtOH (Ethanol), EtOAc (Ethyl acetate), Et 3 N (Triethylamine), EDC1 (l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, HOBt (1-hydroxybenzotriazo
- Another embodiment of the present invention provides a process for the preparation of compounds of formulae (Ii)-(Iix) represent respectively a sub-group of a compound of formula (I), wherein all symbols/variables are as defined earlier unless otherwise stated.
- the process is represented by Scheme- 1.
- Compound of formula (9) was prepared according to the procedure described in Bioorganic & Medicinal Chemistry Letters 19 (2009) 6122-6126 and WO2010/117787.
- a compound of formula (Ii), (Iiv) or (Ivii) can be obtained by reacting a compound of formula (9) with a compound of formula (10a), (10b) or (10c) respectively, in the presence of Pd 2 dba 3 , BINAP, Et 3 N and Cs 2 C0 3 , in a solvent such as 1,4-dioxane and the like at a temperature of about 60 to about 80 °C for about 12 to about 16 h.
- a compound of formula (Ii) to formula (Iii), formula (Iiv) to formula (Iv), formula (Ivii) to formula (Iviii) can be converted using reagents such as 3M LiOH solution, 5N NaOH solution and the like in presence of a suitable solvent such as THF, THF-MeOH and the like.
- a compound of formula (Iii) to formula (Iiii), formula (Iv) to formula (Ivi), formula (Iviii) to formula (Iix) can be converted by using suitable reagents such as HATU, DIPEA or HATU, HOBt, DIPEA or EDCI, HOBt, DIPEA or EDCI, DMAP and the like in presence of a suitable solvent such as DMF, DCM and the like at a temperature of about 20 to about 35°C for about 15 to about 18 h.
- suitable reagents such as HATU, DIPEA or HATU, HOBt, DIPEA or EDCI, HOBt, DIPEA or EDCI, DMAP and the like in presence of a suitable solvent such as DMF, DCM and the like at a temperature of about 20 to about 35°C for about 15 to about 18 h.
- a compound of formula (Ix) where R 1 and R 2 are defined as before can be obtained by reacting a compound of formula (21) with compound of formula (10) in presence of a suitable reagents such as Pd 2 dba 3 , BINAP , Cs 2 C0 3 , Et 3 N or Pd 2 dba 3 , BINAP, KOBu,, Et 3 N, and the like in presence of a suitable solvent such as 1 ,4-Dioxane, and the like at a temperature of about 80 °C for about 15-18 h.
- a suitable reagents such as Pd 2 dba 3 , BINAP , Cs 2 C0 3 , Et 3 N or Pd 2 dba 3 , BINAP, KOBu,, Et 3 N, and the like
- a suitable solvent such as 1 ,4-Dioxane, and the like at a temperature of about 80 °C for about 15-18 h.
- a compound of formula (Ixi) can be obtained by reacting a compound of formula (Ixi)
- a compound of formula (Ixii) can be obtained by reacting a compound of formula (Ixi) with suitable reagents such as HATU, DIPEA or EDCI, HOBt, DIPEA and the like in presence of a suitable solvent such as DMF, DCM and the like at a temperature of about 20-35°C for about 15-18 h.
- suitable reagents such as HATU, DIPEA or EDCI, HOBt, DIPEA and the like
- a suitable solvent such as DMF, DCM and the like at a temperature of about 20-35°C for about 15-18 h.
- Step-1 Synthesis of 4-chloro-N-methoxy-N-methylbutanamide
- Step-2 Synthesis of 4-chloro-l-(2, 5-difluorophenyl)butan-l-one
- Step-3 Synthesis of (S, E)-N-(4-chloro-l-(2, 5-difluorophenyl) butylidene)-2- methylpropane-2-sulfinamide
- Titanium (IV) ethoxide 54.77 g, 240.13 mmol was added to a solution of 4- chloro-l-(2,5-difluorophenyl)butan-l-one(35 g, 160.09 mmol) and (S)-2-methylpropane- 2-sulfinamide (29.1 g, 240.13 mmol) in THF(400mL) with stirring. The mixture was stirred continuously at 70°C for 16h. Reaction mixture was then cooled to a temperature of 20-35°C, quenched with saturated aqueous NH 4 C1 solution, diluted with ethylacetate and filtered. The filtrate was washed with water followed by brine solution. The organic layer was separated, dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford 44.5 g of the title compound as a colourless liquid.
- Step-4 Synthesis of (R)-l-((S)-tert-butylsulfmyl)-2-(2, 5-difluorophenyl) pyrrolidine and (S)-l-((S)-tert-butylsulfinyl)-2-(2, 5-difluorophenyl) pyrrolidine
- Step-5 Synthesis of (R)-2-(2, 5-difluorophenyl) pyrrolidine hydrochloride
- Step-6 Synthesis of (R)-ethyl 5-(2-(2,5-difluorophenyl)pyrrolidin-l- yl)pyrazolo[l,5a]pyridine-3-carboxylate
- Step-1 Synthesis of tert-butyl 2-oxopyrrolidine-l-carboxylate
- Step-2 Synthesis of tert-butyl 5-(2,5-difluorophenyl)-2,3-dihydro-lH-pyrrole-l- carboxylate
- the title compound was prepared by a procedure substantially similar as in Step-6 of Example- 1, using 2-(2,5-difluorophenyl)pyrrolidine in place of (R)-2-(2,5- difluorophenyl) pyrrolidine hydrochloride to afford the crude.
- the crude compound was purified by column chromatography (using silica gel 60-120, and 5% EtOAc in Hexane as eluent) to afford 135 mg of the title compound.
- the title compound was prepared by a method substantially similar to that mentioned in Example -4, using dimethyl amine hydrochloride in place of (S)-pyrrolidin-3- ol.
- the reaction mixture was quenched with cold water, and the solid precipitate obtained was filtered to afford the crude product.
- the crude product was purified by Preparative TLC (Silicagel GF 254 , lOOOu, 20 x 20cm dimension glass plate and 100%EtOAc as eluent) to afford 14 mg of the title compound.
- the reaction mixture was diluted with cold water to obtain a solid precipitate which was then filtered, washed with water, and dried well to afford the crude residue.
- the crude residue obtained was purified by Preparative TLC (using Silicagel GF 254 , lOOOu, 20 x 20cm dimension glass plate and 80%EtOAc in Hexane as eluent) to afford 6 mg of the title compound.
- the title compound was prepared by a similar method to that mentioned in Example-6 to afford the crude product.
- the crude product was purified by Preparative TLC (using Silicagel GF 254 , lOOOu coated 20 x 20cm dimension glass plate and 30%EtOAc in Hexane as eluent) to afford 8 mg of the title compound.
- the title compound was prepared by a similar method as mentioned in Example-4, using 3 -Hydroxy azetidine hydrochloride in place of (S)-3-Pyrrolidinol to afford the crude product.
- the crude product obtained was purified by Preparative TLC (using Silicagel GF254 , lOOOu, coated 20 x 20cm glass plate and 5%MeOH in EtOAc as eluent) to afford 25 mg of (5-(2-(2,5-difluorophenyl)pyrrolidin-l-yl)pyrazolo[l,5-a]pyridin-3-yl)(3- hydroxyazetidin- 1 -yl)methanone.
- the title compound was prepared by a method substantially similar to that mentioned in Example-8, using 4-piperdinol in place of 3 -Hydroxy azetidine hydrochloride to afford the crude product.
- the crude product was purified by Preparative HPLC [Column: 21.2 x 150 x 5um, Zorbax, XDB,C-18(#22), Mobile phase-A: 0.1%TFA in water, B:ACN, Gradient(Time/%B): 0/30, 2/40, 10/70 and Flow rate:20mL/min] to afford 22.1 mg of the title compound..
- the title compound was prepared by a method substantially similar to that mentioned in Example-4, using 2-aminopropane-l,3-diol in place (S)-pyrrolidin-3-ol to afford the crude product.
- the crude product obtained was purified by Preparative HPLC [Column:LUNA-C 18-250*21.2mm, Mobile phase-A: lOmM NH 4 OAc , B: MeOH : ACN(1 : 1), Gradient(Time/%B): 0/40, 2/40, 10/90 and Flow rate:20mL/min] to afford 9 mg of the title compound.
- the title compound was prepared by a method substantially similar to that mentioned in Example-6, using 1 -Methyl piperazine in place of NH 4 C1.
- the reaction mixture was diluted with cold water, extracted with ethylacetate, washed the ethylacetate layer with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford the crude residue.
- Example-2 The title compound was prepared by a method substantially similar to that mentioned in Example-4, using (R)-5-(2-(2, 5-difluorophenyl) pyrrolidin-l-yl) pyrazolo[l,5a]pyridine-3-carboxylic acid (Example-2) and 3 -Hydroxy azetidine hydrochloride in place of (S)-3-Pyrrolidinol to afford the crude product.
- the crude product was purified by Preparative HPLC [Column: Water X-bridge, C-18, 5u, OBD,19 x 150mm, Mobile phase-A: Water, B:ACN, Gradient(Time/%B): 0/30, 2/40, 10/10 and Flow rate: 15mL/min] to afford 98 mg of the title compound(R)-(5-(2-(2,5- difluorophenyl)pyrrolidin- 1 -yl)pyrazolo [ 1 ,5 -a]pyridin-3 -yl)(3 -hydroxyazetidin- 1 - yl)methanone as a white solid.
- the title compound was prepared by the method substantially similar to that mentioned in Example-4, using (S)-3-Pyrrolidinol to afford the crude product, which was purified by Preparative HPLC [Column: water x-bridge, C-18, 5u, OBD,19 x 150mm, Mobile phase-A: 0.1%TFA in water, B:ACN, Gradient(Time/%B): 0/20, 2/30, 10/90 and Flow rate: 15mL/min] 120 mg of the title compoundas an off white solid.
- the title compound was prepared by the method substantially similar to that mentioned in Example- 14, using 3 -Hydroxy azetidine hydrochloride in place of (S)-3- Pyrrolidinol to afford the crude product.
- the crude product obtained was purified by Preparative HPLC [ Column: 21.2 x 150 x 5um, Zorbax, XDB,C-18(#26), Mobile phase- A: 0.1%TFA in water, B:ACN, Gradient(Time/%B): 0/30, 2/40, 10/70 and Flow rate:20mL/min] to afford 60 mg of the title compound as off white solid.
- the title compound was prepared by a method substantially similar to that mentioned in Example-16, using 5,6,7,8-tetrahydroimidazo[l,2-a]pyrazine in place of octahydro-lH-pyrido [1, 2-a] pyrazine to afford the crude compound, which was purified by recrystallisation (DCM: Hexane) to afford 40 mg of the title compound as a yellow solid.
- the title compound was prepared by a method substantially similar to that mentioned in Example-16, using ethyl 5,6,7,8-tetrahydroimidazo[l,2-a] pyrazine-2- carboxylate hydrochloride in place of octahydro-lH-pyrido[l, 2-a]pyrazine to afford the crude compound.
- the crude compound thus obtained was purified by Preparative HPLC [Column: 21.2 x 150 x 5um, Zorbax, XDB,C-18(#26), Mobile phase-A: 0.01%TFA in water, B:ACN, Gradient(Time/%B): 0/40, 2/50, 10/90 and Flow rate:20mL/min] to afford 18 mg of the title compound as an off- white solid.
- the title compound was prepared by a method substantially similar to that mentioned in Example-16, using Octahydropyrrolo[l , 2-a] pyrazine in place of octahydro- lH-pyrido [1, 2-a] pyrazine to afford the crude product.
- the crude product was purified by recrystallization from a mixture of DCM and Hexane to afford 35 mg of the title compound as a yellow solid.
- the title compound was prepared by a similar method to that mentioned in Example-4 to afford the crude product.
- the crude product thus obtained was purified by Preparative HPLC [Column: 21.2 x 250 x 7um, Zorbax, XDB,C-18, Mobile phase-A: 0.01%TFA in water, B:ACN, Gradient(Time/%B): 0/30, 2/40, 10/80 and Flow rate:20mL/min] 65 mg of the title compound.
- the title compound was prepared by a method substantially similar to that mentioned in Example -4, using 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[l,2,4]triazolo[4,3- ajpyrazine hydrochloride in place of (S)-3-Pyrrolidinol to afford the crude product, which was purified by Preparative HPLC [Column: AG/PP/C 18/15-028, Mobile phase-A: Water, B: ACN, Gradient(Time/%B): 0/40, 2/50, 10/80 and Flow rate:20mL/min] to afford 20 mg of the title compound as a yellow solid.
- the title compound was prepared by a similar method to that mentioned in Example-6 to afford the crude product, which was purified by Preparative TLC (Silicagel GF254 , lOOOu, 20 x 20cm dimension glass plate and 5%MeOH in DCM as eluent) to afford 30 mg of the title compound as an off white solid.
- reaction mixture was diluted with ethyl acetate; the organic layer was separated, washed with water followed by brine solution, dried over anhydrous sodium sulphate and concentrated under reduce pressure to afford the crude compound, which was purified by column chromatography (using 60-120 silica gel and 30%EtOAc in Hexane as eluent) to afford 3.5 g of the title compound.
- Methyl magnesium bromide (3.0M in Diethyl ether) (1.5 mL, 4.5 mmol) was added to cold (-10°C) solution of tert-butyl 3-oxoazetidine-l -carboxylate (650 mg, 3.8 mmol) in THF (lOmL) and stirring was continued at 20-35°C for lh. After which the reaction mixture was quenched with saturated aqueous NH 4 C1 solution and extracted with ethylacetate. The organic layer separated was washed with water, dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford the residue. The residue was purified by column chromatography (using 60-120 silica gel and 50%> EtOAc in Hexane as eluent) to afford 430 mg of the title compound.
- the title compound was prepared by a method substantially similar to that mentioned in Example-6, using 3-methylazetidin-3-ol hydrochloride in place of NH 4 C1 along with HOBt (49 mg, 0.29 mmol) to afford the crude product, which was purified by Preparative TLC (Silicagel GF254, lOOOu, 20 x 20cm dimension glass plate and 10%MeOH in DCM as eluent) to afford 37 mg of the title compound as a white solid.
- the title compound was prepared by a method substantially similar to that mentioned in Example-23, using (S)-l-phenyl-2-(pyrrolidin-l-yl)ethanamine in place of 3- methylazetidin-3-ol hydrochloride to afford 33 mg of the title compound.
- the title compound was prepared by a method substantially similar to that mentioned in Example-23, using pyrrolidin-3-ylmethanol in place of 3-methylazetidin-3-ol hydrochloride, to afford the crude product, which was purified by recrystalisation from MeOH to afford 52 mg of the title compound as a white solid.
- the title compound was prepared by a method substantially similar to that mentioned in Example-23, using trans-4-aminocyclohexanol in place of 3-methylazetidin- 3-ol hydrochloride to afford the crude product, which was purified by Preparative TLC (Silicagel GF 254 , lOOOu, 20 x 20cm dimension glass plate and 5% MeOH in EtOAc as eluent) to afford 23 mg of the title compound as a brown solid.
- Example- 16 A method substantially similar to that mentioned in Example- 16 was employed using 1-aminopiperidine in place of Octahydropyrrolo[l, 2-a] pyrazine to afford a crude product, which was purified by Preparative HPLC [Column: 21.2 x 150 x 5um, Zorbax, XDB,C-18(#26), Mobile phase-A: 0.1%TFA in water, B:ACN, Gradient(Time/%B): 0/30, 2/40, 10/70 and Flow rate:20mL/min] to afford 50 mg of the title compound.
- the title compound was prepared by the method substantially similar to that mentioned in Example-6, using 2-amino-2-methylpropane-l,3-diol to afford the crude solid, which was purified by Preparative TLC(Silicagel GF 254 , lOOOu, 20 x 20cm dimension glass plate and 5%MeOH in DCM as eluent) to afford 14 mg of the title compound as a white solid.
- the title compound was prepared by the method substantially similar to that mentioned in Example-6, using 2-aminoethanol to afford the crude product, which was purified by Preparative TLC(Silicagel GF 254 , lOOOu, 20 x 20cm dimension glass plate and 5%MeOH in DCM as eluent) to afford 20 mg of the title compound as an off white solid.
- the title compound was prepared by a method substantially similar to that mentioned in Example-23, using ethyl pyrrolidine-3 -carboxylate in place of 3-Azetidinol hydrochloride to afford the crude product, which was purified by Preparative TLC (Silicagel GF 254 , lOOOu, 20 x 20cm dimension glass plate and 100%EtOAc as eluent) to afford 56 mg of the title compound as a white solid.
- Trifluoroacetic acid (156 mg, 1.4 mmol) was added to a cold (0°C) stirred solution of (R)-tert-butyl 4-(5-(2-(2,5- difluorophenyl)pyrrolidin- 1 -yl)pyrazolo [ 1 ,5 -a]pyridine-3 -carboxamido)piperidine- 1 - carboxylate (39 mg, 0.2 mmol) in DCM (1.2mL). The mixture was stirred continuously at 20-35°C for 4h. The reaction mixture was concentrated under reduced pressure to afford a residue.
- Example-32 A method substantially similar to that mentioned in Example-32 was employed using tert-butyl 3-aminopiperidine-l-carboxylate to afford 21 mg of the title compound as a brown solid.
- Example- 16 A method substantially similar to that mentioned in Example- 16 was employed using Glycine ethylester hydrochloride in place of Octahydropyrrolo[l, 2-a] pyrazine to afford 75 mg of the title compound as a pale brown solid.
- Example-32 A method substantially similar to that mentioned in Example-32 was employed using tert-butylpiperazine-l-carboxylate, to afford 50 mg of the title compound as a yellow solid.
- Example-32 A method substantially similar to that mentioned in Example-32 was employed wherein 4N HCl in Dioxane was used in place of TFA, to afford 16 mg of the title compound as a brownish yellow solid.
- Example 16 A method substantially similar to that mentioned in Example- 16, was used to afford a crude compound, which was purified by Preparative HPLC [Column: Zorbax, Eclipse, C-18, Mobile phase-A: 0.1%TFA in water , B:ACN, Gradient(Time/%B): 0/10, 2/20, 10/60 and Flow rate:20mL/min]to obtain 16 mg of the title compound as a white solid.
- Example-31 A method substantially similar to that mentioned in Example-31 was used to afford a crude product, which was purified by Preparative HPLC [Column: AG/PPC/C18-15/028, Mobile phase-A: 0.1%TFA in water, B: ACN, Gradient(Time/%B): 0/20, 2/30, 10/70 and Flow rate:20mL/min] to afford 8 mg of the title compound as a white solid.
- Example-6 A method substantially similar to that mentioned in Example-6, was employed using (3S)-l-((5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-8-yl)methyl)pyrrolidin-3-ol (W095/21843) to afford a crude product.
- the crude product obtained was purified by Preparative HPLC [Column:21.2 x 150 x 5um, Zorbax, XDB,C-18(#026), Mobile phase- A: 0.1%TFA in water , B:ACN, Gradient(Time/%B): 0/20, 2/30, 10/90 and Flow rate:20mL/min] to afford 5.1 mg of the title compound as a pale brown solid.
- Example-6 A method substantially similar to that mentioned in Example-6, was employed using 3-aminocyclohexanol to obtain a crude product, which was purified by Preparative HPLC [Column: AG/PP/C 18/15-028, Mobile phase-A: 0.1%TFA in water, B: ACN, Gradient(Time/%B): 0/40, 2/50, 8/90 and Flow rate:20mL/min] to afford 30 mg of the title compound as a white solid.
- Example-23 A method substantially similar to that mentioned in Example-23, was employed using azepan-4-ol to afford the crude product, which was purified by Preparative TLC (Silicagel GF 25 4, lOOOu, 20 x 20cm dimension glass plate and 10%MeOH in DCM as eluent) to afford 54 mg of the title compound.
- Example-27 A method substantially similar to that mentioned in Example-27, was employed using 4-methylpiperazin-l -amine to afford a crude product, which was purified by Preparative TLC (Silicagel GF 254 , lOOOu, 20 x 20cm dimension glass plate and 5%MeOH in DCM as eluent) 30 mg of the title compound as an off white solid.
- Preparative TLC Silicagel GF 254 , lOOOu, 20 x 20cm dimension glass plate and 5%MeOH in DCM as eluent
- Ethyl 3-aminocyclohexanecarboxylate was prepared by the method substantially similar to that mentioned method similar to Example-40 using 3 -amino cyclohexane carboxylic acid (Fluorochem). A method substantially similar to that mentioned in Example-23, was employed using ethyl 3-aminocyclohexanecarboxylate to afford 135 mg of the title compound as an off white solid.
- the title compound was prepared by the method substantially similar to that mentioned in Example-41, to afford 32 mg of the title compound as white solid.
- Example-41 A method substantially similar to that mentioned in Example-41 was used to afford 18 mg of the title compound a pale brown solid.
- Example- 16 A method substantially similar to that mentioned in Example- 16, was employed using 2-amino-N,N-dimethylacetamide hydrochloride to afford a crude product, which was purified by Preparative HPLC [using Column:21.2 x 150 x 5um, Zorbax, XDB,C- 18(#022), Mobile phase-A: 0.1%TFA in water , B: MeOH:ACN(l : l), Gradient(Time/%B): 0/50, 2/60, 10/80 and Flow rate:20mL/min]to afford 15 mg of the title compound a pale green solid.
- Preparative HPLC using Column:21.2 x 150 x 5um, Zorbax, XDB,C- 18(#022), Mobile phase-A: 0.1%TFA in water , B: MeOH:ACN(l : l), Gradient(Time/%B): 0/50, 2/60, 10/80 and Flow rate:20mL/min
- Example- 16 A method substantially similar to that mentioned in Example- 16, was employed using , -dimethylethane-l,2-diamine to afford a crude product which was purified by Preparative HPLC [Column: AG/PP/C 18/15-028, Mobile phase-A: 0.1%TFA in water, B: ACN, Gradient(Time/%B): 0/20, 2/30, 10/70 and Flow rate:20mL/min] to 3.8 mg of the title compound as a pale brown solid.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12834589.9A EP2791139B1 (en) | 2011-12-12 | 2012-12-12 | Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors |
| US14/364,518 US9045479B2 (en) | 2011-12-12 | 2012-12-12 | Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors |
| US14/632,078 US9289419B2 (en) | 2011-12-12 | 2015-02-26 | Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4329CH2011 | 2011-12-12 | ||
| IN4329/CHE/2011 | 2011-12-12 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/364,518 A-371-Of-International US9045479B2 (en) | 2011-12-12 | 2012-12-12 | Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors |
| US14/632,078 Division US9289419B2 (en) | 2011-12-12 | 2015-02-26 | Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2013088257A1 true WO2013088257A1 (en) | 2013-06-20 |
Family
ID=47902312
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2012/003022 Ceased WO2013088257A1 (en) | 2011-12-12 | 2012-12-12 | Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors |
| PCT/IB2012/003012 Ceased WO2013088256A1 (en) | 2011-12-12 | 2012-12-12 | Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (trk) inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2012/003012 Ceased WO2013088256A1 (en) | 2011-12-12 | 2012-12-12 | Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (trk) inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (7) | US9045478B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2791138B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5990595B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20140105508A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104114553B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012351748B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014014276A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2858958C (cg-RX-API-DMAC7.html) |
| CL (1) | CL2014001529A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO7071124A2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2791138T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA025352B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2686501T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL233067B (cg-RX-API-DMAC7.html) |
| MX (1) | MX356401B (cg-RX-API-DMAC7.html) |
| WO (2) | WO2013088257A1 (cg-RX-API-DMAC7.html) |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015092610A1 (en) | 2013-12-20 | 2015-06-25 | Pfizer Limited | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
| WO2015159175A1 (en) | 2014-04-15 | 2015-10-22 | Pfizer Inc. | Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety |
| WO2015200341A1 (en) | 2014-06-23 | 2015-12-30 | Dr. Reddy's Laboratories Ltd. | Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain |
| WO2016009296A1 (en) | 2014-07-16 | 2016-01-21 | Pfizer Inc. | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
| WO2016020784A1 (en) | 2014-08-05 | 2016-02-11 | Pfizer Inc. | N-acylpyrrolidine ether tropomyosin-related kinase inhibitors |
| JP2018516264A (ja) * | 2015-05-29 | 2018-06-21 | 无▲錫▼福祈制▲薬▼有限公司Wuxi Fortune Pharmaceutical Co.,Ltd | Janusキナーゼ阻害剤 |
| CN108218754A (zh) * | 2018-01-23 | 2018-06-29 | 广东赛烽医药科技有限公司 | 一种2-(2,5-二氟苯基)吡咯烷的制备方法 |
| CN109593802A (zh) * | 2018-12-24 | 2019-04-09 | 上海健康医学院 | 一种(r)-2-(2,5-二氟苯基)吡咯烷或其盐的制备方法 |
| WO2020016594A1 (en) | 2018-07-19 | 2020-01-23 | Benevolentai Bio Limited | Imidazo[1,2-b]pyridazine derivatives as trk inhibitors |
| WO2020039209A1 (en) | 2018-08-23 | 2020-02-27 | Benevolentai Bio Limited | Imidazo[1,2-b]pyridazines as trk inhibitors |
| WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| CN112979646A (zh) * | 2021-03-08 | 2021-06-18 | 北京富龙康泰生物技术有限公司 | 一种咪唑并吡啶类衍生物 |
| WO2021148807A1 (en) | 2020-01-22 | 2021-07-29 | Benevolentai Bio Limited | Pharmaceutical compositions and their uses |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021148805A1 (en) | 2020-01-22 | 2021-07-29 | Benevolentai Bio Limited | Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds |
| WO2021228248A1 (zh) * | 2020-05-15 | 2021-11-18 | 石药集团中奇制药技术(石家庄)有限公司 | 氮杂稠环酰胺类化合物及其用途 |
| JP2022535838A (ja) * | 2019-06-05 | 2022-08-10 | クワンチョウ ジョーヨー ファーマテック カンパニー,リミティド | ピロロピリミジン類化合物及びその使用 |
| WO2022234287A1 (en) | 2021-05-06 | 2022-11-10 | Benevolentai Bio Limited | Imidazopyridazine derivatives useful as trk inhibitors |
| CN116120323A (zh) * | 2021-11-15 | 2023-05-16 | 石药集团中奇制药技术(石家庄)有限公司 | 固体形式的氮杂稠环酰胺类化合物及其用途 |
| CN116115618A (zh) * | 2021-11-15 | 2023-05-16 | 石药集团中奇制药技术(石家庄)有限公司 | 一种治疗肿瘤的药物 |
| RU2811975C1 (ru) * | 2020-05-15 | 2024-01-19 | СиЭсПиСи ЧЖУНЦИ ФАРМАСЬЮТИКАЛ ТЕКНОЛОДЖИ (ШИЦЗЯЧЖУАН) КО., ЛТД. | Конденсированное аза-гетероциклическое амидное соединение и его применение |
| WO2024118887A1 (en) * | 2022-11-30 | 2024-06-06 | Blueprint Medicines Corporation | N-phenyl-pyrazolo[1,5-a]pyridine-3-carboxamide derivatives as wild type c-kit kinase inhibitors for the treatment of urticaria |
| WO2024123966A1 (en) * | 2022-12-07 | 2024-06-13 | Third Harmonic Bio, Inc. | Compounds and compositions as c-kit kinase inhibitors |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| CN102264736B (zh) | 2008-10-22 | 2013-08-14 | 阵列生物制药公司 | 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| BR122019024201B1 (pt) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica |
| KR20140105508A (ko) * | 2011-12-12 | 2014-09-01 | 닥터 레디스 레보러터리즈 리미티드 | 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘 |
| US9067914B1 (en) | 2013-12-10 | 2015-06-30 | Genzyme Corporation | Tropomyosin-related kinase (TRK) inhibitors |
| CN103819343B (zh) * | 2014-02-17 | 2016-03-23 | 青岛农业大学 | 化合物2-烯丙基-4-氟-6-硝基苯酚的制备方法和农用生物活性 |
| WO2015143652A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| EP3140298A1 (en) | 2014-05-07 | 2017-03-15 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
| AU2015257746B2 (en) * | 2014-05-08 | 2018-11-22 | Bayer Cropscience Aktiengesellschaft | Pyrazolopyridine sulfonamides as nematicides |
| TWI746426B (zh) | 2014-11-16 | 2021-11-21 | 美商亞雷生物製藥股份有限公司 | (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型 |
| MA40698A3 (fr) | 2014-12-18 | 2020-01-31 | Genzyme Corp | Formulations pharmaceutiques d'inhibiteurs de kinase associée à la tropomyosine (trk) |
| CN104672121B (zh) * | 2015-02-16 | 2017-10-24 | 上海华默西医药科技有限公司 | 2r‑(2,5‑二氟苯基)吡咯烷盐酸盐的制备方法 |
| EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| UA125026C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ |
| UA125025C2 (uk) | 2016-04-04 | 2021-12-29 | Локсо Онколоджі, Інк. | Способи лікування дитячих ракових захворювань |
| MX392604B (es) | 2016-05-18 | 2025-03-24 | Array Biopharma Inc | Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo. |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| AU2017348826B2 (en) | 2016-10-28 | 2021-12-02 | Centaurus Biopharma Co., Ltd. | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| PL3621615T3 (pl) | 2017-05-12 | 2024-03-25 | Enanta Pharmaceuticals, Inc. | Inhibitory regulujące sygnał apoptozy kinazy 1 i sposoby ich stosowania |
| WO2018218044A2 (en) | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals Inc | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10450301B2 (en) | 2017-05-25 | 2019-10-22 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2018218042A1 (en) | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10800760B2 (en) | 2017-05-31 | 2020-10-13 | Nantbio, Inc. | Trk inhibition |
| US10738033B2 (en) | 2017-05-31 | 2020-08-11 | Nantbio, Inc. | Trk inhibition |
| CN107286070B (zh) * | 2017-07-19 | 2019-07-16 | 浙江师范大学 | (r)-2-(2,5-二氟苯基)吡咯烷的合成方法及中间体 |
| US10597382B2 (en) | 2017-08-28 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CA3080157A1 (en) | 2017-10-26 | 2019-05-02 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
| CN109867672B (zh) * | 2017-12-02 | 2020-07-07 | 广东东阳光药业有限公司 | 吡唑[1,5-a]吡啶衍生物的盐及其用途 |
| CN109867668B (zh) * | 2017-12-02 | 2021-03-26 | 广东东阳光药业有限公司 | 一种吡唑[1,5-a]吡啶化合物的晶型及其药物组合物和用途 |
| CN109867671B (zh) * | 2017-12-02 | 2020-07-07 | 广东东阳光药业有限公司 | 一种吡唑[1,5-a]吡啶化合物的晶型及其药物组合物和用途 |
| US11179376B2 (en) * | 2017-12-20 | 2021-11-23 | Sunshine Lake Pharma Co., Ltd. | Salts of pyrazolo[1,5-a]pyridine derivative and use thereof |
| WO2019157065A1 (en) | 2018-02-06 | 2019-08-15 | University Of Miami | Inhibitors of the notch transcriptional activation complex kinase ("nack") and methods for use of the same |
| EP3773725A1 (en) | 2018-03-29 | 2021-02-17 | Loxo Oncology Inc. | Treatment of trk-associated cancers |
| IL278368B2 (en) | 2018-05-02 | 2024-06-01 | Enanta Pharm Inc | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2019213239A1 (en) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN108794370A (zh) * | 2018-07-31 | 2018-11-13 | 上海弈柯莱生物医药科技有限公司 | 一种拉罗替尼中间体的制备方法 |
| US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN111171019A (zh) * | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
| WO2020106707A1 (en) | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020198214A1 (en) | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN110015980A (zh) * | 2019-05-14 | 2019-07-16 | 大连联化化学有限公司 | 一种合成叔丁基亚磺酰胺的方法 |
| CN110751853B (zh) * | 2019-10-25 | 2021-05-18 | 百度在线网络技术(北京)有限公司 | 停车位数据的有效性识别方法和装置 |
| CN114829345A (zh) * | 2019-12-27 | 2022-07-29 | 日本烟草产业株式会社 | 酰基磺酰胺化合物及其医药用途 |
| US20230303510A1 (en) * | 2020-07-29 | 2023-09-28 | Ideaya Biosciences, Inc. | Cyclized acetamido derivatives as dna polymerase theta inhibitors |
| CN115772170B (zh) * | 2021-12-03 | 2025-05-16 | 徐诺药业(南京)有限公司 | 一种吡唑并[1,5-a]吡啶衍生物及其制备方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007065664A2 (en) * | 2005-12-08 | 2007-06-14 | Novartis Ag | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors |
| WO2010048314A1 (en) * | 2008-10-22 | 2010-04-29 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
| WO2012116217A1 (en) * | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998050364A1 (en) * | 1997-05-03 | 1998-11-12 | Smithkline Beecham Plc | Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors |
| JP2003231687A (ja) | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
| WO2003101993A1 (en) * | 2002-06-04 | 2003-12-11 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents |
| CA2493701A1 (en) | 2002-07-25 | 2004-02-05 | Pfizer Products Inc. | Isothiazole derivatives useful as anticancer agents |
| US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US20100226881A1 (en) | 2007-07-11 | 2010-09-09 | Auckland Uniservices Limited | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY |
| CA2722418C (en) | 2008-05-13 | 2013-09-17 | Irm Llc | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| KR20140105508A (ko) * | 2011-12-12 | 2014-09-01 | 닥터 레디스 레보러터리즈 리미티드 | 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘 |
-
2012
- 2012-12-12 KR KR1020147018107A patent/KR20140105508A/ko not_active Ceased
- 2012-12-12 EP EP12832784.8A patent/EP2791138B1/en not_active Not-in-force
- 2012-12-12 US US14/364,451 patent/US9045478B2/en not_active Expired - Fee Related
- 2012-12-12 WO PCT/IB2012/003022 patent/WO2013088257A1/en not_active Ceased
- 2012-12-12 AU AU2012351748A patent/AU2012351748B2/en not_active Ceased
- 2012-12-12 ES ES12832784T patent/ES2686501T3/es active Active
- 2012-12-12 EP EP12834589.9A patent/EP2791139B1/en not_active Not-in-force
- 2012-12-12 WO PCT/IB2012/003012 patent/WO2013088256A1/en not_active Ceased
- 2012-12-12 MX MX2014006980A patent/MX356401B/es active IP Right Grant
- 2012-12-12 BR BR112014014276A patent/BR112014014276A2/pt not_active IP Right Cessation
- 2012-12-12 JP JP2014545388A patent/JP5990595B2/ja not_active Expired - Fee Related
- 2012-12-12 CA CA2858958A patent/CA2858958C/en not_active Expired - Fee Related
- 2012-12-12 US US14/364,518 patent/US9045479B2/en not_active Expired - Fee Related
- 2012-12-12 KR KR1020177000318A patent/KR101849143B1/ko not_active Expired - Fee Related
- 2012-12-12 CN CN201280069575.8A patent/CN104114553B/zh not_active Expired - Fee Related
- 2012-12-12 DK DK12832784.8T patent/DK2791138T3/en active
- 2012-12-12 EA EA201400701A patent/EA025352B1/ru not_active IP Right Cessation
-
2014
- 2014-06-10 IL IL233067A patent/IL233067B/en active IP Right Grant
- 2014-06-11 CL CL2014001529A patent/CL2014001529A1/es unknown
- 2014-06-26 CO CO14137528A patent/CO7071124A2/es active IP Right Grant
-
2015
- 2015-02-26 US US14/632,078 patent/US9289419B2/en not_active Expired - Fee Related
- 2015-05-29 US US14/725,683 patent/US9402833B2/en not_active Expired - Fee Related
-
2016
- 2016-05-25 US US15/164,430 patent/US9670207B2/en not_active Expired - Fee Related
-
2017
- 2017-06-01 US US15/611,203 patent/US10047087B2/en not_active Expired - Fee Related
-
2018
- 2018-08-13 US US16/101,753 patent/US10344031B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007065664A2 (en) * | 2005-12-08 | 2007-06-14 | Novartis Ag | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors |
| WO2010048314A1 (en) * | 2008-10-22 | 2010-04-29 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
| WO2012116217A1 (en) * | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
Cited By (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015092610A1 (en) | 2013-12-20 | 2015-06-25 | Pfizer Limited | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
| WO2015159175A1 (en) | 2014-04-15 | 2015-10-22 | Pfizer Inc. | Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety |
| WO2015200341A1 (en) | 2014-06-23 | 2015-12-30 | Dr. Reddy's Laboratories Ltd. | Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain |
| US9394305B2 (en) | 2014-06-23 | 2016-07-19 | Dr. Reddy's Laboratories Ltd. | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors |
| US9782391B2 (en) | 2014-06-23 | 2017-10-10 | Dr. Reddy's Laboratories Ltd. | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors |
| WO2016009296A1 (en) | 2014-07-16 | 2016-01-21 | Pfizer Inc. | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
| WO2016020784A1 (en) | 2014-08-05 | 2016-02-11 | Pfizer Inc. | N-acylpyrrolidine ether tropomyosin-related kinase inhibitors |
| JP2018516264A (ja) * | 2015-05-29 | 2018-06-21 | 无▲錫▼福祈制▲薬▼有限公司Wuxi Fortune Pharmaceutical Co.,Ltd | Janusキナーゼ阻害剤 |
| CN108218754B (zh) * | 2018-01-23 | 2021-05-07 | 广东赛烽医药科技有限公司 | 一种2-(2,5-二氟苯基)吡咯烷的制备方法 |
| CN108218754A (zh) * | 2018-01-23 | 2018-06-29 | 广东赛烽医药科技有限公司 | 一种2-(2,5-二氟苯基)吡咯烷的制备方法 |
| WO2020016594A1 (en) | 2018-07-19 | 2020-01-23 | Benevolentai Bio Limited | Imidazo[1,2-b]pyridazine derivatives as trk inhibitors |
| WO2020039209A1 (en) | 2018-08-23 | 2020-02-27 | Benevolentai Bio Limited | Imidazo[1,2-b]pyridazines as trk inhibitors |
| CN109593802B (zh) * | 2018-12-24 | 2021-10-01 | 上海健康医学院 | 一种(r)-2-(2,5-二氟苯基)吡咯烷或其盐的制备方法 |
| CN109593802A (zh) * | 2018-12-24 | 2019-04-09 | 上海健康医学院 | 一种(r)-2-(2,5-二氟苯基)吡咯烷或其盐的制备方法 |
| WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| JP7261428B2 (ja) | 2019-06-05 | 2023-04-20 | クワンチョウ ジョーヨー ファーマテック カンパニー,リミティド | ピロロピリミジン類化合物及びその使用 |
| US12351590B2 (en) | 2019-06-05 | 2025-07-08 | Guangzhou Joyo Pharmatech Co., Ltd. | Pyrrolopyrimidine compound and use thereof |
| JP2022535838A (ja) * | 2019-06-05 | 2022-08-10 | クワンチョウ ジョーヨー ファーマテック カンパニー,リミティド | ピロロピリミジン類化合物及びその使用 |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148807A1 (en) | 2020-01-22 | 2021-07-29 | Benevolentai Bio Limited | Pharmaceutical compositions and their uses |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021148805A1 (en) | 2020-01-22 | 2021-07-29 | Benevolentai Bio Limited | Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds |
| WO2021228248A1 (zh) * | 2020-05-15 | 2021-11-18 | 石药集团中奇制药技术(石家庄)有限公司 | 氮杂稠环酰胺类化合物及其用途 |
| RU2811975C9 (ru) * | 2020-05-15 | 2024-05-13 | СиЭсПиСи ЧЖУНЦИ ФАРМАСЬЮТИКАЛ ТЕКНОЛОДЖИ (ШИЦЗЯЧЖУАН) КО., ЛТД. | Конденсированное аза-гетероциклическое амидное соединение и его применение |
| KR20230012020A (ko) * | 2020-05-15 | 2023-01-25 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 융합된 아자 헤테로 시클릭 아미드계 화합물 및 이의 용도 |
| US12643906B2 (en) | 2020-05-15 | 2026-06-02 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Fused aza-heterocyclic amide compound and use thereof |
| KR102874188B1 (ko) * | 2020-05-15 | 2025-10-21 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 융합된 아자 헤테로 시클릭 아미드계 화합물 및 이의 용도 |
| CN115551859A (zh) * | 2020-05-15 | 2022-12-30 | 石药集团中奇制药技术(石家庄)有限公司 | 氮杂稠环酰胺类化合物及其用途 |
| CN115551859B (zh) * | 2020-05-15 | 2024-08-27 | 石药集团中奇制药技术(石家庄)有限公司 | 氮杂稠环酰胺类化合物及其用途 |
| JP7495998B2 (ja) | 2020-05-15 | 2024-06-05 | 石薬集団中奇制薬技術(石家庄)有限公司 | アザ縮合環状アミド化合物及びその用途 |
| JP2023525380A (ja) * | 2020-05-15 | 2023-06-15 | 石薬集団中奇制薬技術(石家庄)有限公司 | アザ縮合環状アミド化合物及びその用途 |
| RU2811975C1 (ru) * | 2020-05-15 | 2024-01-19 | СиЭсПиСи ЧЖУНЦИ ФАРМАСЬЮТИКАЛ ТЕКНОЛОДЖИ (ШИЦЗЯЧЖУАН) КО., ЛТД. | Конденсированное аза-гетероциклическое амидное соединение и его применение |
| CN112979646A (zh) * | 2021-03-08 | 2021-06-18 | 北京富龙康泰生物技术有限公司 | 一种咪唑并吡啶类衍生物 |
| WO2022234287A1 (en) | 2021-05-06 | 2022-11-10 | Benevolentai Bio Limited | Imidazopyridazine derivatives useful as trk inhibitors |
| WO2023083356A1 (zh) * | 2021-11-15 | 2023-05-19 | 石药集团中奇制药技术(石家庄)有限公司 | 固体形式的氮杂稠环酰胺类化合物及其用途 |
| WO2023083362A1 (zh) * | 2021-11-15 | 2023-05-19 | 石药集团中奇制药技术(石家庄)有限公司 | 一种治疗肿瘤的药物 |
| CN116115618A (zh) * | 2021-11-15 | 2023-05-16 | 石药集团中奇制药技术(石家庄)有限公司 | 一种治疗肿瘤的药物 |
| CN116115618B (zh) * | 2021-11-15 | 2025-07-08 | 石药集团中奇制药技术(石家庄)有限公司 | 一种治疗肿瘤的药物 |
| CN116120323A (zh) * | 2021-11-15 | 2023-05-16 | 石药集团中奇制药技术(石家庄)有限公司 | 固体形式的氮杂稠环酰胺类化合物及其用途 |
| WO2024118887A1 (en) * | 2022-11-30 | 2024-06-06 | Blueprint Medicines Corporation | N-phenyl-pyrazolo[1,5-a]pyridine-3-carboxamide derivatives as wild type c-kit kinase inhibitors for the treatment of urticaria |
| US20240262826A1 (en) * | 2022-11-30 | 2024-08-08 | Blueprint Medicines Corporation | Wild type kit inhibitors |
| US12448379B2 (en) * | 2022-11-30 | 2025-10-21 | Blueprint Medicines Corporation | Wild type kit inhibitors |
| WO2024123966A1 (en) * | 2022-12-07 | 2024-06-13 | Third Harmonic Bio, Inc. | Compounds and compositions as c-kit kinase inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9289419B2 (en) | Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors | |
| CA2953177C (en) | Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain | |
| JP7001682B2 (ja) | 置換1H-イミダゾ[4,5-b]ピリジン-2(3H)-オン及びGLUN2B受容体調節因子としてのそれらの使用 | |
| CA2976741C (en) | 1-cyano-pyrrolidine compounds as usp30 inhibitors | |
| CA2938294C (en) | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors | |
| CA2787291C (en) | 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds | |
| TW202309039A (zh) | 用於靶向布魯頓氏酪胺酸激酶降解之化合物 | |
| EA038428B1 (ru) | Новое соединение в качестве ингибитора аутотоксина и содержащая его фармацевтическая композиция | |
| EP3717488A1 (en) | Substituted furanopyrimidine compounds as pde1 inhibitors | |
| CN116783199A (zh) | 作为btk抑制剂的吡唑并[1,5-a]吡嗪衍生物 | |
| CA3075477A1 (en) | Novel heterocyclic compounds as cdk8/19 inhibitors | |
| CN116724044B (zh) | 三并杂环类化合物、其制备方法及其应用 | |
| WO2022165530A1 (en) | Small molecule inhibitors of salt inducible kinases | |
| CN117980297A (zh) | 作为egfr抑制剂的取代的氨基吡啶化合物 | |
| AU2023209809B2 (en) | Fused heterocycles as 5-ht2a receptor agonists | |
| CN117425654A (zh) | 2,8-二氮杂螺[4.5]癸烷化合物 | |
| JP2024512595A (ja) | Ddr阻害剤としてのテトラヒドロチエノピリジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12834589 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 14364518 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| REEP | Request for entry into the european phase |
Ref document number: 2012834589 Country of ref document: EP |